Bristol Myers Squibb (BMY) FY2025 10-K Annual Report
Bristol Myers Squibb (BMY) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 11, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Bristol Myers Squibb FY2025 10-K Analysis
Business Overview
- • Core business model focused on oral immunomodulatory and oncology drugs, primarily treating multiple myeloma and CML
- • FDA-approved volume-unlimited generics launched for Revlimid (2026), pomalidomide generics entering U.S. (Mar 2026), dasatinib generics active since Sept 2024
Management Discussion & Analysis
- • Revenue and YoY change: Not disclosed in provided section
- • Profitability or margin change: Not disclosed in provided section
Risk Factors
- • FDA approval of Breyanzi in Dec 2025 for relapsed/refractory MZL after ≥2 systemic therapies, impacting market access and revenue
- • Exposure to Japan's approval landscape with multiple key drug approvals by Ministry of Health Labour and Welfare in 2025, critical for Asia Pacific growth
Bristol Myers Squibb FY2025 Key Financial MetricsXBRL
Revenue
$48.2B
▼ -0.2% YoY
Net Income
$7.1B
▲ +178.8% YoY
Net Margin
14.6%
▲ +3316bp YoY
ROE
38.2%
▲ +9296bp YoY
Total Assets
$90.0B
▼ -2.8% YoY
EPS (Diluted)
$3.46
▲ +178.5% YoY
Operating Cash Flow
$14.2B
▼ -6.8% YoY
Source: XBRL data from Bristol Myers Squibb FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Bristol Myers Squibb
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.